Affiliation:
1. Department of Pharmacolocy and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA
2. Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
Abstract
Preeclampsia (PE) is characterized by maternal hypertension, fetal growth restriction (FGR), and increased inflammation and populations of cytotoxic NK cells (cNKs) and inflammatory T-Helper 17 cells (TH17s). Both cytotoxic NK cells and TH17 cells are heavily influenced via IL-1β signaling. Caspase 1 activity leads to the release of the inflammatory cytokine IL-1β, which is increased in women with PE. Therefore, we tested the hypothesis that the inhibition of Caspase 1 with VX-765 in rats with reduced uterine perfusion pressure (RUPP) will attenuate PE pathophysiology. On gestation day (GD) 14, timed pregnant Sprague–Dawley rats underwent the RUPP or Sham procedure and were separated into groups that received either vehicle or VX-765 (50 mg/kg/day i.p.). On GD19, MAP was measured via carotid catheter and blood and tissues were collected. Bio-Plex and flow cytometry analysis were performed on placental tissues. Placental IL-1β was increased in the RUPP rats vs. the Sham rats and treatment with VX-765 reduced IL-1β in the RUPP rats. Caspase 1 inhibition reduced placental cNKs and TH17s in RUPP rats compared to vehicle-treated RUPP rats. Increased MAP was observed in RUPP rats compared with Sham rats and was reduced in RUPP + VX-765 rats. Placental reactive oxygen species (ROS) were elevated in RUPP rats compared to Sham rats. VX-765 administration reduced ROS in treated RUPP rats. Caspase 1 inhibition increased the number of live pups, yet had no effect on fetal weight or placental efficiency in the treated groups. In conclusion, Caspase 1 inhibition reduces placental IL-1β, inflammatory TH17 and cNK populations, and reduces MAP in RUPP rats. These data suggest that Caspase 1 is a key contributor to PE pathophysiology. This warrants further investigation of Caspase 1 as a potential therapeutic target to improve maternal outcomes in PE.
Funder
National Institutes of Health
Reference53 articles.
1. Hypertension in pregnancy: Pathophysiology and treatment;Braunthal;SAGE Open Med.,2019
2. Mu, T.S., Duran-Stanton, A., Stone, E.A., Zarzabal, L.A., and Loewendorf, A. (2023). Rates of Preeclampsia and Post-preeclamptic Cardiovascular Disease Among US Military Servicewomen: A Retrospective Case-cohort Study. Mil. Med., usad300.
3. Mississippi State Department of Health (2023). Mississippi Maternal Mortality Report 2017–2019, Mississippi State Department of Health.
4. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: A guideline from the american heart association;Mosca;Circulation,2011
5. Association of pro- and anti-inflammatory cytokines in preeclampsia;Aggarwal;J. Clin. Lab. Anal.,2019